Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naive Patients Starting Raltegravir Plus Tenofovir/Emtricitabine.

Trial Profile

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naive Patients Starting Raltegravir Plus Tenofovir/Emtricitabine.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MARAVIBOOST
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jun 2012 New source identified and integrated (European Clinical Trials Database).
    • 23 Jun 2012 Status changed from active, no longer recruiting to completed, according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top